A recent petition has been filed with the Securities and Exchange Commission (SEC), urging the agency to require publicly traded companies to disclose to shareholders the material risks associated with deep supply chain dependence on China [1]. The petition highlights that the American economy is dangerously reliant on China, particularly in sectors critical to national security such as defense, healthcare, technology, and consumer goods [1]. According to the article, China mines roughly 70% of global rare earth elements and processes more than 90% of them, which are essential for products like F-35 jets, submarines, missiles, semiconductors, electric vehicles, and medical devices [1]. In the pharmaceutical sector, China supplies 60% to 70% or more of key active pharmaceutical ingredients and precursor materials for antibiotics and other essential drugs, with much of the remainder flowing through India, which itself depends heavily on Chinese precursors [1]. The article warns that an abrupt break in relations with China—due to war, embargo, or economic coercion—could cripple the U.S. economy and create immediate shortages in critical sectors, escalating to a national health emergency [1]. The piece cites recent Chinese export controls on materials like gallium and germanium as examples of Beijing's willingness to leverage its dominance for geopolitical purposes, referencing the 2010 rare earth embargo against Japan as a precedent [1]. The article criticizes current corporate disclosures on these risks as vague, inconsistent, and inadequate, arguing that investors deserve a clear accounting of just how exposed corporate America has become [1].
CONCLUSION
The SEC petition underscores growing concerns about U.S. corporate dependence on China for critical materials and pharmaceuticals, highlighting significant national security and economic risks. Calls for enhanced transparency could prompt regulatory changes and increased scrutiny of supply chain vulnerabilities, with potential implications for investor confidence and corporate strategy.